Herpes Zoster Risk in the Era of Targeted Immunotherapy: JAK Inhibitors Versus Biologics

Abstract

Keywords

biologics herpes zoster immunomodulators JAK inhibitors pharmacovigilance real-world data

Get full access to this article

View all access options for this article.

References

Yin

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1241954. doi:10.3389/fphar.2023.1241954

Janus kinase inhibitors and the risk of infections: a network meta-analysis across disease indications. Expert Opin Drug Saf. 2025;2025:1-13. doi:10.1080/14740338.2025.2502037

Galloway

Raine

Rivett

Roberts

Dews

Choy

EH.

Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol. 2022;40(7):1432-1441. doi:10.55563/clinexprheumatol/0jdyse

Din

Selinger

Black

Ford

AC.

Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666-675. doi:10.1111/apt.17379

Takanashi

Ohmura

Misaki

, et al. Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol. BMJ Open. 2024;14(11):e090668. doi:10.1136/bmjopen-2024-090668